TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
Brief Summary: To study the effects of synbiotics supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI) clinic with steatosis grade 1 or more will be randomly allocated to receive 2 protexin capsules or placebos for 7 months; both groups will be advised to adherence our diet and exercise program too. At the first and the end of the intervention, lipid profiles, liver enzymes, some inflammatory cytokines, and liver fibrosis will be assessed and compared between groups.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin E | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin E; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Matching placebo; Assigned to Arm(s): 3
B: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: synbiotic | Arm Label: maltodexterin; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): maltodexterin
C: Arm Label: Ginseng trial; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Red ginseng | Intervention Type: DIETARY_SUPPLEMENT; Name: Red ginseng; Assigned to Arm(s): Ginseng trial
D: Arm Label: Chinese bayberry juice; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Chinese bayberry juice | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Chinese bayberry juice; Assigned to Arm(s): Chinese bayberry juice | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
Brief Summary: To study the effects of synbiotics supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI) clinic with steatosis grade 1 or more will be randomly allocated to receive 2 protexin capsules or placebos for 7 months; both groups will be advised to adherence our diet and exercise program too. At the first and the end of the intervention, lipid profiles, liver enzymes, some inflammatory cytokines, and liver fibrosis will be assessed and compared between groups.


Options:
A: Arm Label: Lepicol probiotic & prebiotic formula+simple lifestyle advice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepicol probiotic & prebiotic formula, Other: Simple lifestyle advice | Arm Label: Simple lifestyle advice alone; Type: PLACEBO_COMPARATOR; Interventions: Other: Simple lifestyle advice | Intervention Type: DRUG; Name: Lepicol probiotic & prebiotic formula; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice | Intervention Type: OTHER; Name: Simple lifestyle advice; Assigned to Arm(s): Lepicol probiotic & prebiotic formula+simple lifestyle advice, Simple lifestyle advice alone
B: Arm Label: Neomycin prescribed; Type: EXPERIMENTAL; Interventions: Drug: Neomycin | Arm Label: Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed; Type: EXPERIMENTAL; Interventions: Drug: Lactobacillus casei rhamnosus (Lcr35) | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Lactobacillus casei rhamnosus (Lcr35); Assigned to Arm(s): Probiotics (Lactobacillus casei rhamnosus, Lcr35) prescribed | Intervention Type: DRUG; Name: Neomycin; Assigned to Arm(s): Neomycin prescribed
C: Arm Label: Rifaximin; Type: EXPERIMENTAL; Interventions: Drug: Rifaximin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rifaximin; Assigned to Arm(s): Rifaximin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: synbiotic | Arm Label: maltodexterin; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): maltodexterin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Increasing Physical Activity in Stroke Survivors Using STARFISH, an Interactive Mobile Phone Application: a Feasibility Study
Brief Summary: There is good evidence of the effectiveness of regular physical activity in the primary and secondary prevention of stroke. STARFISH is a smartphone-based application designed as a behavioural change intervention to encourage the user to become more physically active. The study will investigate if using STARFISH for 6 weeks can increase physical activity in people after stroke. Subjects will be randomised to the STARFISH intervention or a control group. Control subjects will not have access to their daily activity count.


Options:
A: Arm Label: m-health stroke rehabilitation; Type: N/A; Interventions: Behavioral: Multimodal Exercise Rehabilitation Program | Intervention Type: BEHAVIORAL; Name: Multimodal Exercise Rehabilitation Program; Assigned to Arm(s): m-health stroke rehabilitation
B: Arm Label: STARFISH intervention; Type: EXPERIMENTAL; Interventions: Behavioral: STARFISH intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: STARFISH intervention; Assigned to Arm(s): STARFISH intervention
C: Arm Label: AARP; Type: N/A; Interventions: N/A
D: Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Follow-up control group | Arm Label: Aerobic exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise group, Behavioral: Follow-up first aerobic exercise group, Behavioral: Follow-up second aerobic exercise group | Arm Label: Follow-up first aerobic exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Follow-up first aerobic exercise group | Arm Label: Follow-up control group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control group, Behavioral: Follow-up control group | Arm Label: Follow-up second aerobic exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Follow-up second aerobic exercise group | Intervention Type: BEHAVIORAL; Name: Aerobic exercise group; Assigned to Arm(s): Aerobic exercise group | Intervention Type: BEHAVIORAL; Name: Control group; Assigned to Arm(s): Follow-up control group | Intervention Type: BEHAVIORAL; Name: Follow-up first aerobic exercise group; Assigned to Arm(s): Aerobic exercise group, Follow-up first aerobic exercise group | Intervention Type: BEHAVIORAL; Name: Follow-up control group; Assigned to Arm(s): Control group, Follow-up control group | Intervention Type: BEHAVIORAL; Name: Follow-up second aerobic exercise group; Assigned to Arm(s): Aerobic exercise group, Follow-up second aerobic exercise group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Increasing Physical Activity in Stroke Survivors Using STARFISH, an Interactive Mobile Phone Application: a Feasibility Study
Brief Summary: There is good evidence of the effectiveness of regular physical activity in the primary and secondary prevention of stroke. STARFISH is a smartphone-based application designed as a behavioural change intervention to encourage the user to become more physically active. The study will investigate if using STARFISH for 6 weeks can increase physical activity in people after stroke. Subjects will be randomised to the STARFISH intervention or a control group. Control subjects will not have access to their daily activity count.


Options:
A: Arm Label: STARFISH intervention; Type: EXPERIMENTAL; Interventions: Behavioral: STARFISH intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: STARFISH intervention; Assigned to Arm(s): STARFISH intervention
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Exercise | Arm Label: Arm 2; Type: OTHER; Interventions: Other: Stroke education | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Stroke education; Assigned to Arm(s): Arm 2
C: Arm Label: Trunk training; Type: EXPERIMENTAL; Interventions: Other: Trunk training | Arm Label: Cognitive exercises; Type: SHAM_COMPARATOR; Interventions: Other: Cognitive exercises | Intervention Type: OTHER; Name: Trunk training; Assigned to Arm(s): Trunk training | Intervention Type: OTHER; Name: Cognitive exercises; Assigned to Arm(s): Cognitive exercises
D: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard care | Arm Label: Standard Care + VEM; Type: EXPERIMENTAL; Interventions: Other: Standard Care + VEM | Intervention Type: OTHER; Name: Standard Care + VEM; Assigned to Arm(s): Standard Care + VEM | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)
Brief Summary: Evaluate linagliptin in terms of glycemic control as defined by HbA1c after 24 weeks of treatment and in terms of renal efficacy as defined by changes in albuminuria (UACR) after 24 weeks of treatment.


Options:
A: Arm Label: 1Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: CIIIT | Intervention Type: DRUG; Name: CIIIT; Assigned to Arm(s): Treatment
B: Arm Label: linagliptin 5mg; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin 5mg | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Linagliptin 5mg; Assigned to Arm(s): linagliptin 5mg
C: Arm Label: Linagliptin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Insulin degludec (IDeg); Type: EXPERIMENTAL; Interventions: Drug: insulin degludec | Arm Label: Insulin glargine (IGlar); Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): Insulin degludec (IDeg) | Intervention Type: DRUG; Name: insulin glargine; Assigned to Arm(s): Insulin glargine (IGlar)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Educational Feasibility Trial: 'In Situ Simulation' Versus 'Off Site Simulation' in Obstetric Emergencies and the Effect on Knowledge, Safety-attitudes, Team Performance, Stress, and Motivation
Brief Summary: Care for pregnant is a field where unexpected emergencies occur, however emergencies are rare and hence competences difficult to learn. Therefore, it can be relevant to use simulation-based medical education. Many questions on how simulation can optimise learning remain unanswered. A major question is how simulation settings as 'in situ simulation' (i.e. in the actual patient care unit) versus 'off site simulation' (i.e. in training rooms or simulation center) impact learning.

Objectives: To study the effect of 'in situ simulation' versus 'off site simulation' on learning outcome, safety-attitudes, team performance and clinical performance in the simulated setting plus stress and motivational inducing effect of simulation settings.

Design: Randomised trial. Primary outcome: Written knowledge-test. Exploratory outcomes: Safety Attitudes Questionnaire, team- and clinical performance score, validated stress inventory, salivary cortisol, Intrinsic Motivation Inventory and questionnaire on perceptions of the simulation and organisational changes needed.

Perspective: To provide new knowledge on contextual effects of different simulation settings.


Options:
A: Arm Label: NRP Training (Intervention); Type: EXPERIMENTAL; Interventions: Procedure: Neonatal Resuscitation | Arm Label: Control; Type: OTHER; Interventions: Procedure: Neonatal Resuscitation | Intervention Type: PROCEDURE; Name: Neonatal Resuscitation; Assigned to Arm(s): Control, NRP Training (Intervention)
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PRONTO training; Type: EXPERIMENTAL; Interventions: Other: PRONTO training | Intervention Type: OTHER; Name: PRONTO training; Assigned to Arm(s): PRONTO training
C: Arm Label: In situ simulation; Type: EXPERIMENTAL; Interventions: Other: In situ simulation | Arm Label: Off site simulation; Type: ACTIVE_COMPARATOR; Interventions: Other: Off site simulation | Intervention Type: OTHER; Name: In situ simulation; Assigned to Arm(s): In situ simulation | Intervention Type: OTHER; Name: Off site simulation; Assigned to Arm(s): Off site simulation
D: Intervention Type: BEHAVIORAL; Name: Labor and Delivery Team Coordination Course; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Respiratory Muscle Strength, Functional Capacity and Subjective Outcome - Effects of Inspiratory Muscle Training After Lung Cancer Surgery, a Randomized Controlled Trial
Brief Summary: The purpose of this study is to evaluate the effects of postoperative inspiratory muscle training on the recovery of respiratory muscle strength in high risk patients referred for lung cancer surgery. Furthermore, to assess longitudinal changes in respiratory muscle strength, physical capacity and health-related quality of life after lung cancer surgery


Options:
A: Arm Label: Inspiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Inspiratory muscle training, Other: Placebo comparator: standard physiotherapy | Arm Label: Standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo comparator: standard physiotherapy | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Inspiratory muscle training | Intervention Type: OTHER; Name: Placebo comparator: standard physiotherapy; Assigned to Arm(s): Inspiratory muscle training, Standard physiotherapy
B: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical exercise, Other: best supportive care | Arm Label: No exercise; Type: OTHER; Interventions: Other: best supportive care | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): Exercise | Intervention Type: OTHER; Name: best supportive care; Assigned to Arm(s): Exercise, No exercise
C: Arm Label: Control - usual care; Type: OTHER; Interventions: Other: Usual care | Arm Label: Exercise + usual care; Type: OTHER; Interventions: Other: Usual care, Other: Exercise | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control - usual care, Exercise + usual care | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise + usual care
D: Arm Label: Exercise Intervention Program (EIP); Type: EXPERIMENTAL; Interventions: Behavioral: Exercise Intervention, Other: Care-Management-Phone-Calls | Arm Label: Care-Management-Phone-Calls (CMPC); Type: ACTIVE_COMPARATOR; Interventions: Other: Care-Management-Phone-Calls | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention Program (EIP) | Intervention Type: OTHER; Name: Care-Management-Phone-Calls; Assigned to Arm(s): Care-Management-Phone-Calls (CMPC), Exercise Intervention Program (EIP)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Respiratory Muscle Strength, Functional Capacity and Subjective Outcome - Effects of Inspiratory Muscle Training After Lung Cancer Surgery, a Randomized Controlled Trial
Brief Summary: The purpose of this study is to evaluate the effects of postoperative inspiratory muscle training on the recovery of respiratory muscle strength in high risk patients referred for lung cancer surgery. Furthermore, to assess longitudinal changes in respiratory muscle strength, physical capacity and health-related quality of life after lung cancer surgery


Options:
A: Arm Label: Resistance training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Resistance training
B: Arm Label: Inspiratory muscle training; Type: EXPERIMENTAL; Interventions: Other: Inspiratory muscle training, Other: Placebo comparator: standard physiotherapy | Arm Label: Standard physiotherapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo comparator: standard physiotherapy | Intervention Type: OTHER; Name: Inspiratory muscle training; Assigned to Arm(s): Inspiratory muscle training | Intervention Type: OTHER; Name: Placebo comparator: standard physiotherapy; Assigned to Arm(s): Inspiratory muscle training, Standard physiotherapy
C: Arm Label: Physical training; Type: OTHER; Interventions: Other: Physical training | Arm Label: As usual; Type: OTHER; Interventions: Other: As usual | Intervention Type: OTHER; Name: Physical training; Assigned to Arm(s): Physical training | Intervention Type: OTHER; Name: As usual; Assigned to Arm(s): As usual
D: Arm Label: PLEACE 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Anterolateral thoracotomy, Procedure: Posterolateral thoracotomy | Arm Label: PLEACE 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: VATS, Procedure: Anterolateral Thoracotomy | Intervention Type: PROCEDURE; Name: Anterolateral thoracotomy; Assigned to Arm(s): PLEACE 1 | Intervention Type: PROCEDURE; Name: Posterolateral thoracotomy; Assigned to Arm(s): PLEACE 1 | Intervention Type: PROCEDURE; Name: VATS; Assigned to Arm(s): PLEACE 2 | Intervention Type: PROCEDURE; Name: Anterolateral Thoracotomy; Assigned to Arm(s): PLEACE 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, 12-Week, Parallel Group, Placebo-Controlled Proof of Concept Study to Investigate the Efficacy and Safety of RG7314 in Individuals With Autism Spectrum Disorders (ASD)
Brief Summary: This multi-center, randomized, double-blind, parallel group, placebo-controlled, proof of concept study will investigate the efficacy and safety of RG7314 in adult participants with ASD. In Stage I of the study, participants will be randomized in 2:1 to receive daily oral doses of 1.5 milligrams (mg) RG7314 or placebo for 12 weeks. After an independent safety review, the study may proceed to Stage II. In Stage II of the study, additional participants will be randomized in 2:1 to receive daily oral doses of 4 mg RG7314 or placebo for 12 weeks. After an independent safety review, Stage III will be started wherein additional participants will be randomized in 2:1 to receive daily oral doses of 10 mg RG7314 or placebo for 12 weeks. During Stage III, safety will be reviewed by independent safety review twice and if no safety signal is observed, then additional participants will be randomized in 1:1:1 either to receive 1.5 milligrams per day (mg/day) or 10 mg/day RG7314 orally or placebo for 12 weeks in Stage IV.


Options:
A: Arm Label: Intranasal Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Intranasal Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
D: Arm Label: Trichuris Suis Ova (TSO); Type: EXPERIMENTAL; Interventions: Drug: Trichuris Suis Ova | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Trichuris Suis Ova | Intervention Type: DRUG; Name: Trichuris Suis Ova; Assigned to Arm(s): Placebo, Trichuris Suis Ova (TSO)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, 12-Week, Parallel Group, Placebo-Controlled Proof of Concept Study to Investigate the Efficacy and Safety of RG7314 in Individuals With Autism Spectrum Disorders (ASD)
Brief Summary: This multi-center, randomized, double-blind, parallel group, placebo-controlled, proof of concept study will investigate the efficacy and safety of RG7314 in adult participants with ASD. In Stage I of the study, participants will be randomized in 2:1 to receive daily oral doses of 1.5 milligrams (mg) RG7314 or placebo for 12 weeks. After an independent safety review, the study may proceed to Stage II. In Stage II of the study, additional participants will be randomized in 2:1 to receive daily oral doses of 4 mg RG7314 or placebo for 12 weeks. After an independent safety review, Stage III will be started wherein additional participants will be randomized in 2:1 to receive daily oral doses of 10 mg RG7314 or placebo for 12 weeks. During Stage III, safety will be reviewed by independent safety review twice and if no safety signal is observed, then additional participants will be randomized in 1:1:1 either to receive 1.5 milligrams per day (mg/day) or 10 mg/day RG7314 orally or placebo for 12 weeks in Stage IV.


Options:
A: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
B: Arm Label: Arbaclofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314
D: Arm Label: All patients admitted to the ophthalmologic emergency unit.; Type: N/A; Interventions: N/A

Answer: C